Inventory |
3 Months Ended | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2025 | ||||||||||||||||||||||||||||
| Inventory Disclosure [Abstract] | ||||||||||||||||||||||||||||
| Inventory |
4. Inventory
Inventory is stated at the lower of cost and net realizable value and consists of work-in-process. The Company began capitalizing inventory costs following FDA approval of ORLYNVAH in October 2024, and inventory production commenced in February 2025. The Company has not recorded any significant inventory write-downs since that time. No allowance for excess, damaged, and obsolete inventory was held at March 31, 2025. The Company currently uses a limited number of third-party contract manufacturing organizations to produce its inventory. |
|||||||||||||||||||||||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|